TCG Labs Soleil: Startup & Funding Seminar for UCSF Innovators

• Are you researching new therapeutic hypotheses?

• Has your work elucidated a new drug target or a new way to think about an old target?

• Would you be interested in founding a company to advance your ideas?

What is TCG Labs-Soleil? TCG-Soleil is a venture capital fund and a biotech company – combining the best features of both to optimize drug discovery and development. TCG-Soleil provides the money to translate therapeutic hypotheses and IP into real therapies and all the capabilities of a top caliber biotech company.

What is TCG Labs-Soleil looking for? Exciting new therapeutic hypotheses or IP (targets or molecules) that are grounded by genetic or human data and address a major unmet need. No platforms.

Why TCG Labs-Soleil? We simplify the process to bring important new drugs to patients as efficiently as possible. You bring the idea and we bring the funding, veteran team, R&D labs, and drug discovery know-how. You receive the benefits of a start-up with none of the hassle (i.e., keep your day job!). Start turning your work into a drug today!

How does it work? Apply through UCSF Innovation Ventures. If TCG Labs-Soleil selects your proposal, we can either form a company with you as a founder and scientific advisor, dedicate at least $200,000 of funding to your lab in the form of a sponsored research agreement, or both. You receive equity. We commit to fully funding and operating the company. UCSF IV and TCG work together to complete the license.

We are accepting super simple applications on a rolling basis through July 30th under a master CDA with UCSF. We guarantee detailed feedback for every submission. We will schedule a follow-up Zoom meeting to discuss submissions of interest. Finalists will receive an onsite visit.

JOIN A SEMINAR TO LEARN MORE

June 18th, 12:00-1:30 pm in room MH-1400, Mission Hall; lunch will be provided

HOW TO APPLY

Submit your answers to the 4 questions below (please keep entire response <1-page, font size 12 or greater, short/concise is better, the drug target is the most important) to [email protected]

1. What is the specific unmet medical need your proposal can address?

2. How does your drug target-of-interest address this unmet need at the level of disease pathophysiology?

3. How is this idea better than existing therapies already approved by the FDA or currently in human clinical trials?

4. What data has your lab generated to support this hypothesis (if any)?

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Darya Bubman